Two pharmaceutical companies, Sarepta and Marathon, presented updates on medicines for DMD patients.  Because of several controversial issues around pricing, Marathon was under pressure to explain their pricing model for a product that had essentially been on the market for ~40 years.  In an effort to slow down and hear customers, the CEO of Marathon sent Pat Furlong an email with a temporary measure aimed at allaying concerns about an immediate price hike for US patients who needed the medication.

The following video is Pat Furlong reading a letter from the CEO.

Here is a letter from Marathon to the DMD community:

Here, also, is a relevant page on Marathon's website: http://marathonpharma.com/treatments/ensuring-access/